Hit #40

Shire Pharma(SHPGY) today announced that it is buying Transkaryotic Therapies (TKTX) in an all cash deal valuing Transkaryotic stock at $37/share, a 20% premium to its most recent price.

This offer represents a premium of 176% over my average cost of $13.4/share.

Shire itself is a takeover target and that may happen within a couple of years. It is worth buying now - I don't own any yet.